Piper Sandler Initiates Coverage On Fennec Pharmaceuticals with Overweight Rating, Announces Price Target of $18
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $18.
Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $18.